1365-2893/asset/JVH_left.gif?v=1&s=b49347dbb27ed46f9f14bd61c3304105cb5a53be)
Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine
Article first published online: 6 OCT 2008
DOI: 10.1111/j.1365-2893.2008.01047.x
© 2008 The Authors. Journal compilation © 2008 Blackwell Publishing Ltd
Additional Information
How to Cite
Viganò, M., Lampertico, P., Facchetti, F., Lunghi, G. and Colombo, M. (2008), Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine. Journal of Viral Hepatitis, 15: 922–924. doi: 10.1111/j.1365-2893.2008.01047.x
Publication History
- Issue published online: 12 NOV 2008
- Article first published online: 6 OCT 2008
- Received March 2008; accepted for publication July 2008
- Abstract
- Article
- References
- Cited By
Keywords:
- adefovir dipivoxil;
- antiviral treatment;
- HBV DNA;
- hepatitis B;
- lamivudine resistance;
- suboptimal response
Summary. Nine patients with lamivudine-resistant chronic hepatitis B infection who had been treated with adefovir 10 mg/day and had had a suboptimal response but did not have genotypic resistance to adefovir were treated with high-dose adefovir (20 mg/day). The response to the increased dose of adefovir was compared with the response in 15 patients with a suboptimal response who did not receive an increase in the dose of adefovir. The increase in the dose of adefovir did not lead to a significant reduction in hepatitis B DNA when compared with patients maintained on the standard dose. These data suggest that increasing the dose of adefovir in patients with a suboptimal response does not lead to an improved response.